Development and assessment of human adenovirus type 11 as a gene transfer vector

Journal of Virology

Volumn 79, Issue 8, 2005, Pages 5090-5104

  Stone, Daniel ^a   Ni, Shaoheng ^a   Li, Zong Yi ^a   Gaggar, Anuj ^a   DiPaolo, Nelson ^a   Feng, Qinghua ^a   Sandig, Volker ^b   Lieber, André ^a,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b PROBIOGEN AG   (Germany)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CAPSID PROTEIN; CHIMERIC PROTEIN; DRUG CARRIER; E1B PROTEIN; GLYCOPROTEIN E1; MEMBRANE COFACTOR PROTEIN; NEUTRALIZING ANTIBODY; VIRUS RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL MATURATION; CIRCULATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG EFFICACY; EMBRYO; ESCHERICHIA COLI; FIBER; GENE ACTIVITY; GENE DELETION; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSDUCTION; GENOME ANALYSIS; HEMATOPOIETIC STEM CELL; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; INFUSION; INJECTION; KIDNEY; LIVER; LUNG; MEDICAL ASSESSMENT; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PREVALENCE; PRIORITY JOURNAL; RAT; RODENT; SEROTYPE; SPLEEN; TRANSGENE; VIRUS GENOME; VIRUS INFECTIVITY; VIRUS PARTICLE; VIRUS TRANSFORMATION;

ADENOVIRUSES, HUMAN; BASE SEQUENCE; CELL LINE; DENDRITIC CELLS; GENE TRANSFER TECHNIQUES; GENETIC COMPLEMENTATION TEST; GENETIC VECTORS; HEMATOPOIETIC STEM CELLS; HUMANS; KIDNEY; PLASMIDS; POLYMERASE CHAIN REACTION; RECOMBINANT FUSION PROTEINS; SEQUENCE DELETION; SEROTYPING;

EID: 16244407740     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.79.8.5090-5104.2005     Document Type: Article

References (74)

1. Aoki, K., and Y. Tagawa. 2002. A twenty-one year surveillance of adenoviral conjunctivitis in Sapporo, Japan. Int. Ophthalmol. Clin. 42:49-54.
2. Arthur, J. F., L. H. Butterfield, M. D. Roth, L. A. Bui, S. M. Kiertscher, R. Lau, S. Dubinett, J. Glaspy, W. H. McBride, and J. S. Economou. 1997. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther. 4:17-25.
3. Berkner, K. L., and P. A. Sharp. 1983. Generation of adenovirus by transfection of plasmids. Nucleic Acids Res. 11:6003-6020.
4. Bernt, K. M., S. Ni, Z. Y. Li, D. M. Shayakhmetov, and A. Lieber. 2003. The effect of sequestration by nontarget tissues on anti-tumor efficacy of systemically applied, conditionally replicating adenovirus vectors. Mol. Ther. 8:746-755.
5. Caravokyri, C., and K. N. Leppard. 1995. Constitutive episomal expression of polypeptide IX (pIX) in a 293-based cell line complements the deficiency of pIX mutant adenovirus type 5. J. Virol. 69:6627-6633.
6. Carlson, C. A., D. M. Shayakhmetov, and A. Lieber. 2002. An adenoviral expression system for AAV rep78 using homologous recombination. Mol. Ther. 6:91-98.
7. Chanock, R. M., W. Ludwig, R. J. Heubner, T. R. Cate, and L. W. Chu. 1966. Immunization by selective infection with type 4 adenovirus grown in human diploid tissue cultures. I. Safety and lack of oncogenicity and tests for potency in volunteers. JAMA 195:445-452.
8. Chartier, C., E. Degryse, M. Gantzer, A. Dieterle, A. Pavirani, and M. Mehtali. 1996. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J. Virol. 70:4805-4810.
9. Cichon, G., S. Boeckh-Herwig, D. Kuemin, C. Hoffmann, H. H. Schmidt, E. Wehnes, W. Haensch, U. Schneider, U. Eckhardt, R. Burger, and P. Pring-Akerblom. 2003. Titer determination of Ad5 in blood: a cautionary note. Gene Ther. 10:1012-1017.
10. D'Ambrosio, E., N. Del Grosso, A. Chicca, and M. Midulla. 1982. Neutralizing antibodies against 33 human adenoviruses in normal children in Rome. J. Hyg. 89:155-161.
11. Gaggar, A., S. Ni, and A. Lieber. 2004. Vector host interactions of group B adenoviruses in CD46 transgenic mice. Mol. Ther. 9:S53.
12. Gaggar, A., D. M. Shayakhmetov, and A. Lieber. 2003. CD46 is a cellular receptor for group B adenoviruses. Nat. Med. 9:1408-1412.
13. Gall, J., A. Kass-Eisler, L. Leinwand, and E. Falck-Pedersen. 1996. Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes. J. Virol. 70:2116-2123.
14. Gao, W., P. D. Robbins, and A. Gambotto. 2003. Human adenovirus type 35: nucleotide sequence and vector development. Gene Ther. 10:1941-1949.
15. Girardi, A. J., M. R. Hilleman, and R. E. Zwickey. 1964. Tests in hamsters for oncogenic quality of ordinary viruses including adenovirus type 7. Proc. Soc. Exp. Biol. Med. 115:1141-1150.
16. Green, M. 1970. Oncogenic viruses. Annu. Rev. Biochem. 39:701-756.
17. Havenga, M. J., A. A. Lemckert, O. J. Ophorst, M. van Meijer, W. T. Germeraad, J. Grimbergen, M. A. van Den Doel, R. Vogels, J. van Deutekom, A. A. Janson, J. D. de Bruijn, F. Uytdehaag, P. H. Quax, T. Logtenberg, M. Mehtali, and A. Bout. 2002. Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease. J. Virol. 76:4612-4620.
18. Hierholzer, J. C., T. Adrian, L. J. Anderson, R. Wigand, and J. W. Gold. 1988. Analysis of antigenically intermediate strains of subgenus B and D adenoviruses from AIDS patients. Arch. Virol. 103:99-115.
19. Hierholzer, J. C., R. Wigand, L. J. Anderson, T. Adrian, and J. W. Gold. 1988. Adenoviruses from patients with AIDS: a plethora of serotypes and a description of five new serotypes of subgenus D (types 43-47). J. Infect. Dis. 158:804-813.
20. Hofmann, C., P. Loser, G. Cichon, W. Arnold, G. W. Both, and M. Strauss. 1999. Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo. J. Virol. 73:6930-6936.
21. Hsu, E. C., R. E. Dorig, F. Sarangi, A. Marcil, C. Iorio, and C. D. Richardson. 1997. Artificial mutations and natural variations in the CD46 molecules from human and monkey cells define regions important for measles virus binding. J. Virol. 71:6144-6154.
22. Huebner, R. J., M. J. Casey, R. M. Chanock, and K. Schell. 1965. Tumors induced in hamsters by a strain of adenovirus type 3: sharing of tumor antigens and "neoantigens" with those produced by adenovirus type 7 tumors. Proc. Natl. Acad. Sci. USA 54:381-388.
23. Imperiale, M. J., and S. Kochanek. 2004. Adenovirus vectors: biology, design, and production. Curr. Top. Microbiol. Immunol. 273:335-357.
24. Kajon, A. E., A. S. Mistchenko, C. Videla, M. Hortal, G. Wadell, and L. F. Avendano. 1996. Molecular epidemiology of adenovirus acute lower respiratory infections of children in the south cone of South America (1991-1994). J. Med. Virol. 48:151-156.
25. Kemper, C., M. Leung, C. B. Stephensen, C. A. Pinkert, M. K. Liszewski, R. Cattaneo, and J. P. Atkinson. 2001. Membrane cofactor protein (MCP; CD46) expression in transgenic mice. Clin. Exp. Immunol. 124:180-189.
26. Knaan-Shanzer, S., I. Van Der Velde, M. J. Havenga, A. A. Lemckert, A. A. De Vries, and D. Valerio. 2001. Highly efficient targeted transduction of undifferentiated human hematopoietic cells by adenoviral vectors displaying fiber knobs of subgroup B. Hum. Gene Ther. 12:1989-2005.
27. Krasnykh, V. N., G. V. Mikheeva, J. T. Douglas, and D. T. Curiel. 1996. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J. Virol. 70:6839-6846.
28. Kremer, E. J., S. Boulin, M. Chillon, and O. Danos. 2000. Canine adenovirus vectors: an alternative for adenovirus-mediated gene transfer. J. Virol. 74:505-512.
29. Krougliak, V., and F. L. Graham. 1995. Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants. Hum. Gene Ther. 6:1575-1586.
30. Larson, V. M., A. J. Girardi, M. R. Hilleman, and R. E. Zwickey. 1965. Studies of oncogenicity of adenovirus type 7 virus in hamsters. Proc. Soc. Exp. Biol. Med. 118:15-24.
31. Lieber, A., C. Y. He, I. Kirillova, and M. A. Kay. 1996. Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo. J. Virol. 70:8944-8960.
32. Lieber, A., C. Y. He, L. Meuse, D. Schowalter, I. Kirillova, B. Winther, and M. A. Kay. 1997. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J. Virol. 71:8798-8807.
33. Mack, C. A., W. R. Song, H. Carpenter, T. J. Wickham, I. Kovesdi, B. G. Harvey, C. J. Magovern, O. W. Isom, T. Rosengart, E. Falck-Pedersen, N. R. Hackett, R. G. Crystal, and A. Mastrangeli. 1997. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum. Gene Ther. 8:99-109.
34. Mei, Y. F., K. Lindman, and G. Wadell. 2002. Human adenoviruses of subgenera B, C, and E with various tropisms differ in both binding to and replication in the epithelial A549 and 293 cells. Virology 295:30-43.
35. Mei, Y. F., K. Lindman, and G. Wadell. 1998. Two closely related adenovirus genome types with kidney or respiratory tract tropism differ in their binding to epithelial cells of various origins. Virology 240:254-266.
36. Mittereder, N., K. L. March, and B. C. Trapnell. 1996. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J. Virol. 70:7498-7509.
37. Mizuguchi, H., and M. A. Kay. 1998. Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum. Gene Ther. 9:2577-2583.
38. Morral, N., W. O'Neal, K. Rice, M. Leland, J. Kaplan, P. A. Piedra, H. Zhou, R. J. Parks, R. Velji, E. Aguilar-Cordova, S. Wadsworth, F. L. Graham, S. Kochanek, K. D. Carey, and A. L. Beaudet. 1999. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc. Natl. Acad. Sci. USA 96:12816-12821.
39. Morrison, M. D., D. Reid, D. Onions, N. Spibey, and L. Nicolson. 2002. Generation of E3-deleted canine adenoviruses expressing canine parvovirus capsid by homologous recombination in bacteria. Virology 293:26-30.
40. Nakabayashi, H., K. Taketa, K. Miyano, T. Yamane, and J. Sato. 1982. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res. 42:3858-3863.
41. MN env/rev recombinant virus. Gene Ther. 10:326-336.
42. Neering, S. J., S. F. Hardy, D. Minamoto, S. K. Spratt, and C. T. Jordan. 1996. Transduction of primitive human hematopoietic cells with recombinant adenovirus vectors. Blood 88:1147-1155.
43. Nevels, M., S. Rubenwolf, T. Spruss, H. Wolf, and T. Dobner. 1997. The adenovirus E4orf6 protein can promote E1A/E1B-induced focus formation by interfering with p53 tumor suppressor function. Proc. Natl. Acad. Sci. USA 94:1206-1211.
44. Nwanegbo, E., E. Vardas, W. Gao, H. Whittle, H. Sun, D. Rowe, P. D. Robbins, and A. Gambotto. 2004. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin. Diagn. Lab. Immunol. 11:351-357.
45. Ostapchuk, P., and P. Hearing. 2001. Pseudopackaging of adenovirus type 5 genomes into capsids containing the hexon proteins of adenovirus serotypes B, D, or E. J. Virol. 75:45-51.
46. Rea, D., M. J. Havenga, M. van Den Assem, R. P. Sutmuller, A. Lemckert, R. C. Hoeben, A. Bout, C. J. Melief, and R. Offringa. 2001. Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells. J. Immunol. 166:5236-5244.
47. Roelvink, P. W., A. Lizonova, J. G. Lee, Y. Li, J. M. Bergelson, R. W. Finberg, D. E. Brough, I. Kovesdi, and T. J. Wickham. 1998. The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J. Virol. 72:7909-7915.
48. Sakurai, F., H. Mizuguchi, and T. Hayakawa. 2003. Efficient gene transfer into human CD34+ cells by an adenovirus type 35 vector. Gene Ther. 10:1041-1048.
49. Sakurai, F., H. Mizuguchi, T. Yamaguchi, and T. Hayakawa. 2003. Characterization of in vitro and in vivo gene transfer properties of adenovirus serotype 35 vector. Mol. Ther. 8:813-821.
50. Segerman, A., J. P. Atkinson, M. Marttila, V. Dennerquist, G. Wadell, and N. Arnberg. 2003. Adenovirus type 11 uses CD46 as a cellular receptor. J. Virol. 77:9183-9191.
51. Seshidhar Reddy, P., S. Ganesh, M. P. Limbach, T. Brann, A. Pinkstaff, M. Kaloss, M. Kaleko, and S. Connelly. 2003. Development of adenovirus serotype 35 as a gene transfer vector. Virology 311:384-393.
52. Shayakhmetov, D. M., C. A. Carlson, H. Stecher, Q. Li, G. Stamatoyannopoulos, and A. Lieber. 2002. A high-capacity, capsid-modified hybrid adenovirus/adeno-associated virus vector for stable transduction of human hematopoietic cells. J. Virol. 76:1135-1143.
53. Shayakhmetov, D. M., Z. Y. Li, S. Ni, and A. Lieber. 2004. Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors. J. Virol. 78:5368-5381.
54. Shayakhmetov, D. M., Z. Y. Li, S. Ni, and A. Lieber. 2002. Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases. Cancer Res. 62:1063-1068.
55. Shayakhmetov, D. M., Z. Y. Li, V. Ternovoi, A. Gaggar, H. Gharwan, and A. Lieber. 2003. The interaction between the fiber knob domain and the cellular attachment receptor determines the intracellular trafficking route of adenoviruses. J. Virol. 77:3712-3723.
56. Shayakhmetov, D. M., and A. Lieber. 2000. Dependence of adenovirus infectivity on length of the fiber shaft domain. J. Virol. 74:10274-10286.
57. + cells by a retargeted adenovirus vector. J. Virol. 74:2567-2583.
58. Shayakhmetov, D., A. Gaggar, S. Ni, Z.-Y. Li, and A. Lieber. Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity, J. Virol., in press.
59. Sirena, D., B. Lilienfeld, M. Eisenhut, S. Kalin, K. Boucke, R. R. Beerli, L. Vogt, C. Ruedl, M. F. Bachmann, U. F. Greber, and S. Hemmi. 2004. The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. J. Virol. 78:4454-4462.
60. Skog, J., Y. F. Mei, and G. Wadell. 2002. Human adenovirus serotypes 4p and 11p are efficiently expressed in cell lines of neural tumour origin. J. Gen. Virol. 83:1299-1309.
61. Sova, P., X. W. Ren, S. Ni, K. M. Bernt, J. Mi, N. Kiviat, and A. Lieber. 2004. A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Mol. Ther. 9:496-509.
62. Stecher, H., D. M. Shayakhmetov, G. Stamatoyannopoulos, and A. Lieber. 2001. A capsid-modified adenovirus vector devoid of all viral genes: assessment of transduction and toxicity in human hematopoietic cells. Mol. Ther. 4:36-44.
63. Stevenson, S. C., M. Rollence, J. Marshall-Neff, and A. McClelland. 1997. Selective targeting of human cells by a chimeric adenovirus vector containing a modified fiber protein. J. Virol. 71:4782-4790.
64. Stone, D., A. Furthmann, V. Sandig, and A. Lieber. 2003. The complete nucleotide sequence, genome organization, and origin of human adenovirus type 11. Virology 309:152-165.
65. Tsujimura, A., K. Shida, M. Kitamura, M. Nomura, J. Takeda, H. Tanaka, M. Matsumoto, K. Matsumiya, A. Okuyama, Y. Nishimune, M. Okabe, and T. Seya. 1998. Molecular cloning of a murine homologue of membrane cofactor protein (CD46): preferential expression in testicular germ cells. Biochem. J. 330:163-168.
66. van der Eb, A. J., and F. L. Graham. 1980. Assay of transforming activity of tumor virus DNA. Methods Enzymol. 65:826-839.
67. Varghese, R., Y. Mikyas, P. L. Stewart, and R. Ralston. 2004. Postentry neutralization of adenovirus type 5 by an antihexon antibody. J. Virol. 78:12320-12332.
68. Varnavski, A. N., Y. Zhang, M. Schnell, J. Tazelaar, J. P. Louboutin, Q. C. Yu, A. Bagg, G. P. Gao, and J. M. Wilson. 2002. Preexisting immunity to adenovirus in rhesus monkeys fails to prevent vector-induced toxicity. J. Virol. 76:5711-5719.
69. Vlachaki, M. T., A. Hernandez-Garcia, M. Ittmann, M. Chhikara, L. K. Aguilar, X. Zhu, B. S. The, E. B. Butler, S. Woo, T. C. Thompson, H. Barrera-Saldana, and E. Aguilar-Cordova. 2002. Impact of preimmunization on adenoviral vector expression and toxicity in a subcutaneous mouse cancer model. Mol. Ther. 6:342-348.
70. Vogels, R., D. Zuijdgeest, R. van Rijnsoever, E. Hartkoorn, I. Damen, M. P. de Bethune, S. Kostense, G. Penders, N. Helmus, W. Koudstaal, M. Cecchini, A. Wetterwald, M. Sprangers, A. Lemckert, O. Ophorst, B. Koel, M. van Meerendonk, P. Quax, L. Pamitti, J. Grimbergen, A. Bout, J. Goudsmit, and M. Havenga. 2003. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J. Virol. 77:8263-8271.
71. Watanabe, T., C. Kuszynski, K. Ino, D. G. Heimann, H. M. Shepard, Y. Yasui, D. C. Maneval, and J. E. Talmadge. 1996. Gene transfer into human bone marrow hematopoietic cells mediated by adenovirus vectors. Blood 87:5032-5039.
72. Wold, W. S., J. K. Mackey, P. Rigden, and M. Green. 1979. Analysis of human cancer DNA's for DNA sequence of human adenovirus serotypes 3, 7, 11, 14, 16, and 21 in group B1. Cancer Res. 39:3479-3484.
73. Zahradnik, J. M., M. J. Spencer, and D. D. Porter. 1980. Adenovirus infection in the immunocompromised patient. Am. J. Med. 68:725-732.
74. Zhang, L. Q., Y. F. Mei, and G. Wadell. 2003. Human adenovirus serotypes 4 and 11 show higher binding affinity and infectivity for endothelial and carcinoma cell lines than serotype 5. J. Gen. Virol. 84:687-695.